Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3891935 | 0.83 | MTNR1A (0.50) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL1454240 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL10932816 | 0.80 | PPARG (0.49) | SLC6A4KDM4ECYP1A2MAPT | |
| SCHEMBL4665496 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL7404204 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL7582723 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL331604 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL27629520 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL11658593 | 0.78 | SLC6A4 (0.39) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL2092589 | 0.78 | MTNR1A (0.55) | MTNR1AMTNR1BSLC6A4LMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1685150-A2 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005047303-A2 | NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| EP-0069290-B1 | AZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1984-09-05 | — | — | EP | disclosed |
| US-4456608-A | Azole compounds, their preparation, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1984-06-26 | — | — | US | disclosed |
| US-4380546-A | Azole compounds, their preparation, their use for crop treatment, and agents for this purpose | BASF AKTIENGESELLSCHAFT (DE) | 1983-04-19 | — | — | US | disclosed |
| EP-0069290-A1 | Azole compounds, process for their preparation and fungicides containing them | BASF Aktiengesellschaft (DE) | 1983-01-12 | — | — | EP | disclosed |
| EP-0040350-A1 | Azole compounds, their preparation, their use in treating plants, and agents therefor | BASF Aktiengesellschaft (DE) | 1981-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | MTNR1A 538/4885MTNR1B 661/4885SLC6A4 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.